Exploring Analyst Estimates for Johnson & Johnson (JNJ) Q4 Earnings, Beyond Revenue and EPSZacks Investment Research • 01/15/26
TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomidePRNewsWire • 01/14/26
Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 01/14/26
Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual MeetingPRNewsWire • 01/13/26
Johnson & Johnson (JNJ) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 01/12/26
Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top courtReuters • 01/12/26
Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancerPRNewsWire • 01/10/26
Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation InvestmentsBusiness Wire • 01/09/26
JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic LupusZacks Investment Research • 01/07/26
Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug AdministrationBusiness Wire • 01/07/26
Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 studyPRNewsWire • 01/06/26